Sling Therapeutics raises $123 million for thyroid eye disease late-stage trial
Sling Therapeutics said it raised $123 million to advance a late-stage trial of its experimental oral drug for thyroid eye disease.
Drug developer Sling Therapeutics said on Wednesday it raised $123 million to advance a late-stage trial of its experimental oral treatment for thyroid eye disease. The disease causes inflammation and swelling around the eyes, which can lead to eye bulging and vis…